Breast Cancer RESULT INTERPRETATION THERAPRINT OVERVIEW
|
|
- Jonathan Webb
- 5 years ago
- Views:
Transcription
1 Breast Cancer PAGE 1 OF 7 Patient: DOB: Patient #: Gender: Customer Ref.: SPECIMEN Requisition: Collection Date: Date Received: Report Date: Specimen Site: Tumor Origin: Unspecified Breast PHYSICIAN Ordering Physician: Account: Address: City, St., Zip: Country: RESULT INTERPRETATION 43 y/o female with newly diagnosed Grade III TNBC breast cancer by core needle biopsy. T1b,NX,MX with Risk Basal signature by BluePrint and Mammaprint. ERBB2 signature was also co-expressed(+0.308) on BluePrint but without corresponding positive expression of HER2 by TargetPrint. TargetPrint was consistent with TNBC. Endocrine Therapy: There is no mrna expression for any endocrine gene activation including the androgen receptor. No mrna expression evidence for any meaningful responsiveness to endocrine therapy. Chemotherapy: no clear chemotherapy class sensitivity, by mrna expression. There appears to be average sensitivity to alkylators and anti-metabolites. There appears to be a stronger mrna expression signal for sensitivity to anthracyclines, platinum agants and topoisomerase inhibitors. Taxanes do not appear to uniquely sensitive but there is an mrna expression for sensitivity to eribulin mesylate in this basal tumor that appears to have up-regulation of the mesenchymal-stemcell component. Targeted Therapy: Wildtype for EGFR, KRAS, BRAF and PIK3CA. There is very low expression of BRCA1 suggesting that PARP inhibitors may be beneficial. There is moderately high expression of ERBB2 mrna consistent with the positive ERBB2 signature seen on BluePrint as well as a very high expression of both EGFR and PIK3CA mrna. This patient may have a low level Her2 activating mutation and if anti-her2 therapy were considered, there might be consideration of using TDM-1 or Trastuzumab in combination with an irreversible inhibitor to Her2 such as neratinib as opposed to lapatinib as these functional mutations are frequently resistant to reversible inhibitors such as lapatinib. The high PIK3CA mrna expression suggests benefit from a PIK3CA inhibitor. Clinical trials are listed on the website. THERAPRINT OVERVIEW TheraPrint for breast cancer patients provides an individualized genomic fingerprint of the patient s tumor and correlates the results with a likely response to a variety of hormonal, chemo and biological therapies. TheraPrint provides gene expression results for 55 biomarkers and variant analysis results for 4 genes that have been identified as potential markers for predicting response. Some of these markers are directly targeted by existing drugs or a drug class; others have been shown to be involved in resistance or response mechanisms. Within categories, the gene biomarkers are listed according to drug class. The clinical relevance statement is a short description of how expression and mutation presence is linked to response or resistance to the associated drugs. TheraPrint biomarkers have been investigated in research and clinical studies for their potential involvement in the context of cancer therapy. The quality and quantity of the supporting literature for each biomarker are indicated by the level of evidence. Detailed information about each biomarker, reference lists and more information can be found in the appendix or via the link The selection of any, all or none of the matched drugs/agents resides solely with the discretion of the treating physician.
2 PAGE 2 OF 7
3 PAGE 3 OF 7 THERAPRINT RESULTS SERM (e.g. tamoxifen, raloxifene, fulvestrant) BCL2 X BCL2 expression in ER-positive patients is correlated with positive response to endocrine therapy. ESR1 X expression of Estrogen Receptor 1 (ESR1) is correlated to response to endocrine therapies. ESR2 X ESR2 expression is directly correlated with prognosis and response to endocrine therapies. PR (PGR) X expression of Progesterone Receptor (PR) is correlated to response to endocrine therapies. CCND1 X ER-positive breast cancer patients with high expression of cyclin D1 may not benefit from endocrine therapy. EPHA2 X expression of EPHA2 in ER-positive breast cancer is linked to poor prognosis and poor response to endocrine therapy. HIF1A X expression of HIF1A is a marker of poor prognosis and is linked to poor endocrine therapy response. PDGFRA X expression of PDGFRA may be predictive for resistance to tamoxifen treatment in ER-positive patients. TIMP1 X expression of TIMP1 is linked to endocrine therapy resistance. VEGFR2 (KDR) X expression of VEGFR2 is linked to endocrine therapy resistance in ER-positive patients. ERBB4 (HER4) X Loss of HER4 expression is a marker for resistance to endocrine therapy. Aromatase Inhibitors (e.g. anastrozole, letrozole, exemestane) ESR1 X expression of ESR1 is linked to response to Aromatase Inhibitors in post menopausal patients. PR (PGR) X expression of PR is correlated to response to endocrine therapies. ER-positive and PR-positive expression are linked to a greater response than PR alone. Anti-androgen (e.g. abitarone, bicalutamide, flutamide) AR X expression of androgen receptor (AR) might be linked to response to anti-androgen treatment. Alkylating Agents (e.g. temozolomide, cyclophosphamide) MGMT X In triple negative patients, low expression of MGMT is correlated with response to alkylation drugs. TIMP1 X TIMP1 expression is linked to lack of response to alkylation agent therapy. ABCB1 X ABCB1 expression is linked to resistance to alkylating agents. Anti-Metabolites (e.g. 5-fluorouracil, gemcitabine, methotrexate) CES2 X CES2 expression is linked to response to anti-metabolite chemotherapy. DCK X expression levels of DCK are indicative for positive response to nucleoside analogs. TYMP X TYMP expression is linked to response to anti-metabolite chemotherapy. TS (TYMS) X expression of TYMS is linked to a better response and survival benefit from anti-metabolite chemotherapy. ABCG2 X ABCG2 expression is linked to resistance to anti-metabolite chemotherapy. RRM1 X expression of RRM1 is suspected to be indicator of poor response to anti-metabolite chemotherapy. RRM2B X expression levels of RRM2B might be linked to anti-metabolite therapy resistance. TIMP1 X TIMP1 expression is linked to lack of response to anti-metabolite chemotherapy.
4 PAGE 4 OF 7 Anthracyclines (e.g. doxorubicin, epirubicin) TOP2A X expression levels of TOP2A in HER2-positive patients are linked to poor prognosis and better response to anthracycline based chemotherapy. BRCA1 X Patients with low BRCA1 expression level may benefit from anthracycline based chemotherapy. GRB7 X expression level of GRB7 is associated with poor prognosis and in triple negative patients and may be indicative for resistance to anthracycline based chemotherapy. YWHAZ X expression of YWHAZ is linked to resistance to anthracycline based chemotherapy. Mitotic Inhibitors/ Taxanes (e.g. docetaxel, ixabepilone, eribulin mesylate) BCL2 X expression of BCL2 is linked to response to taxane based chemotherapy. SPARC X SPARC expression is linked to response to taxane based chemotherapy, especially nab-paclitaxel. GRB7 X expression of GRB7 is linked to resistance to taxane based chemotherapy. Platinum Based (e.g. carboplatin, cisplatin) CES2 X expression of CES2 might be linked to positive response to platinum based chemotherapy. BRCA1 X Patients with low BRCA1 expression level may benefit from platinum based chemotherapy. ERCC1 X expression of ERCC1 is linked to better response to platinum based chemotherapy. Topoisomerase Inhibitors (e.g. irinotecan, etoposide) AURKA X levels of AURKA indicate proliferative activity and more likely response to anti-proliferative chemotherapy. MKI67 X levels of MKI67 indicate proliferative activity and more likely response to anti-proliferative chemotherapy. TOP2A X expression levels of TOP2A might be linked to better response to toposoimerase II inhibitors. ral TOP1 X expression of TOP1 is associated with poor prognosis and linked to resistance to topoisomerase inhibitors. ABCB1 X expression of ABCB1 may predict multidrug resistance. ABCG2 X expression levels of ABCG2 might be linked to multidrug resistance. HIF1A X expression of HIF1A is a marker of poor prognosis and is linked to poor chemotherapy response. NFKB1 X expression of NFKB1 is involved in tumor growth, progression and resistance to chemotherapy. TIMP1 X expression of TIMP1 is linked to chemotherapy resistance.
5 PAGE 5 OF 7 Angiogenesis Inhibitor (e.g. bevacizumab) PECAM1 X PECAM1 expression is associated with poor prognosis and might be linked to response to bevacizumab. VEGFA X expression of VEGFA is weakly linked to response to angiogenesis inhibitors. VEGFB X expression of VEGFB is weakly linked to response to angiogenesis inhibitors. VEGFR1 (FLT1) X VEGFR1 expression may be an indicator for poor prognosis and indicative for response to anti-vegfr antibodies. VEGFR2 (KDR) X expression of VEGFR2 is a sign of increased vascularization and is linked to response to angiogenesis inhibitors. HIF1A X expression of HIF1A is linked to acquired anti-angiogenesis inhibitor resistance. HER2/ EGFR Inhibitors (e.g. trastuzumab, lapatinib, cetuximab, gefitinib, pertuzumab) ERBB2 (HER2) X Amplification and high expression of ERBB2/HER2 is correlated to response to Herceptin and other HER2-inhibitors. ERBB3 (HER3) X expression of ERBB3 is correlated to poor prognosis and might be indicative for improved response to HER2/HER3 targeting agents. ERBB4 (HER4) X expression of ERBB4 might be a favorable prognostic marker and an indication for efficient response to Herceptin treatment in HER2-positive patients. EGFR X EGFR expression might be linked to better response to anti-egfr antibodies like pertuzumab. EGFR variant analysis wt Tumors without EGFR mutations may be sensitive to anti-egfr monoclonal antibody therapy. PIK3CA variant analysis wt PIK3CA mutations in exon 9 (p.glu542, p.glu545) and exon 20 (p.his1047) may be indicative for resistance to anti- HER2 inhibitors. Patients wildtype for PIK3CA may benefit. EPHA2 X expression of EPHA2 in HER2-positive patients indicate poor prognosis and poor response to anti-her2 therapy. IGF1R X IGF1R expression can indicate resistance to HER2-targeted therapy in HER2-positive cancers. PIK3CA X expression PIK3CA could indicate resistance to HER2 and EGFR targeting drugs. PTEN X PTEN gene expression can be predictive for reduced responsiveness to HER2-inhibitors. HER2/ PI3K-downstream pathway inhibitors (e.g. everolimus, temsirolimus, vemurafenib, dabrafenib, sorafinib) BRAF X Very high expression of BRAF maybe indicates improved response to kinase inhibitors. KRAS X Very high expression of KRAS may indicate improved response to kinase inhibitors. MAP2K1 (MEK1) X expression of MAP2K1 is potentially linked to response to MEK1/2 inhibitors. MAP3K3 X MAP3K3 activates MEK1/2 which is linked to response to MEK1/2 inhibitors. MTOR X expression of MTOR may be linked to response to mtor inhibitors. PIK3CA X Very high expression of PIK3CA might be indicative for response to kinase inhibitors. PIK3R1 X expression of PIK3R1 might indicate a high activity of PI3-Kinase and better response to PI3-Kinase inhibitors. PTEN X PTEN gene expression can be predictive for increased responsiveness to AKT/mTOR inhibitors. BRAF variant analysis wt Patients with a p.val600 mutation might be eligible for clinical studies with BRAF-and MEK inhibitors. KRAS variant analysis wt MEK inhibitors are emerging as an important drug class to consider for KRAS Gly12 or Gly13 mutant patients. PIK3CA variant analysis wt Patients with PIK3CA activating mutations in exon 9 (p.glu542, p.glu545) or exon 20 (p.his1047) might have better response to PI3K/AKT/mTOR pathway inhibitors.
6 PAGE 6 OF 7 Other Kinase Inhibitors (e.g. aurora kinase inhibitor, foretinib) AURKA X expression of AURKA is likely to predict response to Aurora-A inhibitors. cmet (MET) X expression of MET has been linked to poor prognosis and better response to MET inhibitors. EPHA2 X expression of EPHA2 might be indicative for response to multikinase inhibitors like dasatinib. KIT X expression of KIT is a marker of basal-like breast cancer and may be linked to response to kinase inhibitors. LYN X expression of LYN is linked to response to Src kinase inhibitors, particularly in basal/ triple negative breast cancer. PDGFRA X expression of PDGFRA is linked to response to Tyrosine Kinase Inhibitors (TKI). SRC X SRC expression is a marker for triple negative subtype and might indicate improved response to SRC kinase inhibitors like dasatinib. Mismatch repair system modulators/ PARP Inhibitors (e.g. olaparib, veliparib, AG014699) BRCA1 X Patients with low expression of BRCA1 may benefit from PARP inhibitors. RAD51B X Rad51 expression is associated with increased resistance to DNA damaging agents. IGFR Inhibitor (e.g. figitumumab) IGF1R X expression of IGF1R is linked to response to IGFR inhibitors. Inhibitors of Apoptosis (e.g. YM155) BIRC5 X expression of BIRC5 (survin) are linked to therapy response to specific inhibitors like YM1555. BH3 Mimetic BCL2 X Patients with high expression of BCL2 might benefit from antisense therapy oblimersen sodium or specific inhibitors of Bcl-2, Bcl-xL and Bcl-w, like ABT-737. Proteosome Inhibitor (e.g. bortezomib) NFKB1 X NFKB1 is activated in HER2-positive breast cancer. Combining proteosome inhibitor with HER2 targeted therapy is linked to response. Demethylating Agents CDH1 X expression of E-Cadherin (CDH1) is a marker for lobular breast cancer and is linked to response to demethylating drug therapies. Bisphosphonates (or diphosphonates) PTHLH X expression of PTHLH is strongly linked to metastatic spread to bone and maybe indicative of poor response to bisphosphonates.
7 PAGE 7 OF 7 THERAPRINT ASSAY DETAILS GENE EXPRESSION Using DNA microarray technology, TheraPrint measures the mrna level of genes that are of potential interest in the context of cancer therapy. The expression of each gene is assessed in multifold to assure precise results. For most genes, there are no known absolute cut-offs to determine whether a given expression level is truly high/low or what exact level of expression determines sensitivity or resistance. To provide an indication of whether a gene expression is rather low or rather high, the patient s gene expression is compared to the gene expression of a reference population. The reference population was established using 2274 specimens from breast cancer patients untreated with chemotherapy. Each of the samples was hybridized onto the Agendia micro-array in the same fashion as the patient s sample. The reference distribution is different for each gene, but is translated to an expression range of 5% to 95% in order to standardize the results. The level of the patient s gene expression is compared to the reference distribution and indicated as X in the colored bars. to high expression is depicted from left to right. Drug sensitivity (green) and resistance (blue) are depicted as gradients with the deepest color indicating the highest likelihood of resistance or sensitivity. THERAPRINT ASSAY DETAILS VARIANT ANALYSIS This variant analysis assay qualitatively detects specific mutations in DNA of the KRAS, BRAF, PIK3CA and EGFR genes using mutation specific primers in combination with real time PCR. The detailed list of variants that can be detected are listed in the appendix. This highly sensitive PCR assay is capable of reproducibly detecting mutations in samples with as little as 1 to 5% mutated DNA. The variant analysis provides a binary result, wildtype or mutant. The result is linked to sensitivity (green) or resistance (blue) of specific drug classes. THERAPRINT ASSAY LEVEL OF EVIDENCE The level of evidence for each gene is assigned according to the literature level of evidence defined by the U.S. Preventive Services Task Force1 and indicated by circles with three empty circles for lowest level and three filled circles for highest evidence level. = Level 3 Late phase clinical trial evidence in humans and a strong association between gene expression or mutational variant and the responsiveness to therapy for the drug class under consideration = Level 2 Multiple studies in humans have shown moderate cause-effect relationship between the gene expression or mutational variant and the responsiveness to therapy for the drug class under consideration = Level 1 Preclinical evidence or evidence in other cancer types or cell lines indicate predictive value of marker = Level 0 No direct evidence to support the role of the gene in the activity of the drug class under consideration, but strong biological connection between the marker and drug response THERAPRINT ASSAY TUMOR PERCENTAGE Agendia requires specimens with a 30% tumor content or greater. The tumor percentage in this specimen was: 70% For more background information on all genes, drug classes and links to clinical studies, please see: Jia-Perng Jennifer Wei, MD, PhD Laboratory Director Neil Barth, M.D., F.A.C.P. Chief Medical Officer For In Vitro Diagnostic Use Caution: Federal law restricts this device to sale by or on the order of a physician. Agendia is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Decisions regarding care and treatment should not be based on a single test such as this test. Rather, decisions on care and treatment should be based on the independent medical judgment of the treating physician taking into consideration all available information concerning the patient s condition, including other pathological tests, in accordance with the standard of care in a given community. This test was performed at Agendia s Irvine, California laboratory (05D ) Reference: 1) Guirguis-Blake J, Calonge N, Miller T, Siu A, Teutsch S, Whitlock E (2007). Current processes of the U.S. Preventive Services Task Force: refining evidence-based recommendation development. Ann. Intern. Med. 147 (2): PMID
Comprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.
Comprehensive Genomic Profiling, in record time Accurate. ly Proven. Fast. PCDx advantages Comprehensive genomic profiling, in record time PCDx Comprehensive Genomic Profiling (CGP) provides precise information
Triple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
StrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient
StrandAdvantage Tissue-Specific Cancer Genomic Tests Empowering Crucial First-Line Therapy Decisions for Your Patient Harness the power of precision medicine with StrandAdvantage Precision medicine in
Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
Metastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
Looking Beyond the Standard-of- Care : The Clinical Trial Option
1 Looking Beyond the Standard-of- Care : The Clinical Trial Option Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor
Adjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
Mdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
Tratamiento neoadyuvante: Enfermedad residual como marcador de resistencia Carlos L. Arteaga, MD Vanderbilt-Ingram Cancer Center Vanderbilt
Tratamiento neoadyuvante: Enfermedad residual como marcador de resistencia Carlos L. Arteaga, MD Vanderbilt-Ingram Cancer Center Vanderbilt University Neoadjuvant (preoperative) therapy Surgery Systemic
It is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
Multimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
10/15/2012. Inflammatory Breast Cancer vs. LABC: Different Biology yet Subtypes Exist
Triple-Negative Breast Cancer: Optimizing Treatment for Locally Advanced Breast Cancer Beth Overmoyer MD Director, Inflammatory Breast Cancer Program Dana Farber Cancer Institute Overview Inflammatory
Transforming treatment and improving survival for ovarian cancer patients. March 25, 2012
Transforming treatment and improving survival for ovarian cancer patients March 25, 2012 Introduction to Clearity Foundation Clearity profiling panel Overview Interpretation of results utilizing the Diane
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Everolimus in combination with exemestane for the treatment of advanced or metastatic HER2 negative, oestrogen
Recent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
Breast cancer. Prof Arlene Chan Medical Oncologist Director Breast Clinical Trials Unit, Mount Hospital Vice-Chair Breast Cancer Research Centre - WA
Breast cancer rof Arlene Chan Medical Oncologist Director Breast Clinical Trials Unit, Mount Hospital Vice-Chair Breast Cancer Research Centre - WA Breast cancer Incidence of Breast Cancer by Stage at
Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy
Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy 1 st st International Oncological Conference Wrocław, October 6 th, 2012 Dr. Frank Kischkel Individualized Cancer Therapy:
Gene expression in cancer diagnostics
Gene expression in cancer diagnostics Aron Eklund eklund@cbs.dtu.dk Cancer Systems Biology group Center for Biological Sequence Analysis Technical University of Denmark Introduction to Systems Biology
Systemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
Breast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
Disease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
Treatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) Approved Kinase Inhibitors September 2014 Sponsored by PamGene www.pamgene.com The Kinase Activity Profiling
Appendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2
Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles
RECENT ADVANCES BREAST CANCER THERAPY. Bhanu Priya B, 2 Basavanna P L, 1 Postgraduate, 2 Professor Department of Pharmacology, MMC&RI, Mysore
RECENT ADVANCES BREAST CANCER THERAPY 1 Bhanu Priya B, 2 Basavanna P L, 1 Postgraduate, 2 Professor Department of Pharmacology, MMC&RI, Mysore Brief overview Introduction Etiology Pathogenesis Symptoms
Dr C K Kwan. Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK
HA Convention 2013 Dr C K Kwan MBChB, FRCR, FHKCR, FHKAM, MPM, CPI, MAppMgt(Hlth) Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK To personalize cancer
Intro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
Index. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, for early-stage triple-negative breast cancer, 740 742 in older early-stage breast cancer patients, 790 795 anti-her2-directed
Mechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal
Overcoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
Molecular Characterization of Breast Cancer: The Clinical Significance
Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville
Adjuvant Systemic Therapy In Early Brest Cancer
Ductal Carcinoma In-situ and Early Breast Cancer Symposium With International Contributions Adjuvant Systemic Therapy In Early Brest Cancer Vicente Valero, M.D., F.A.C.P. Professor of Medicine and Deputy
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Herceptin) Reference Number: ERX.SPA.42 Effective Date: 07.01.16 Last Review Date: 05/17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the
Triple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
Clinical Policy: Lapatinib (Tykerb) Reference Number: CP.PHAR.79 Effective Date: Last Review Date: 11.17
Clinical Policy: (Tykerb) Reference Number: CP.PHAR.79 Effective Date: 10.01.11 Last Review Date: 11.17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
Karel A. Dicke M.D., Ph.D.
Karel A. Dicke M.D., Ph.D. 1 Genomic Medicine Chemotherapy is selected on the basis of biomarkers in tumor cells. Chemotherapy kills tumor cells. Precision medicine: drugs targeting mutations in single
Beyond the Guidelines: Clinical Investigators Provide Their Perspectives on Current Strategies and Ongoing Research in the Management of Breast Cancer
Beyond the Guidelines: Clinical Investigators Provide Their Perspectives on Current Strategies and Ongoing Research in the Management of Breast Cancer Wednesday, December 11, 2013 7:30 PM 9:30 PM San Antonio,
Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer * Substances without published evidence based on at
Triple Negative Breast Cancer
GASCO 2016 San Antonio Breast Cancer Symposium Review Triple Negative Breast Cancer Amelia Zelnak, MD, MSc Atlanta Cancer Care Northside Hospital Cancer Institute Disclosures: consultant for Novartis,
Radiation therapy Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Chemotherapy Chemotherapy is a cancer
Dr. Pravin D. Potdar. M.Sc, Ph.D, D.M.L.T.,DHE, DMS
Molecular Profiling of Cancer Cells Strategies for Developing Biomarkers for Targeted Therapies of Cancer Dr. Pravin D. Potdar. M.Sc, Ph.D, D.M.L.T.,DHE, DMS Head, Department of Molecular Medicine and
ENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones
ENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative
Presenter: Dr. Suman Rao May 13, 2016
Presenter: Dr. Suman Rao May 13, 2016 1 2010 Breast Cancer Estimates 207,090 NEW CASES 4% Melanoma of Skin 2% Thyroid 31% Breast 13% Lung & Bronchus 2% Pancreas 11% Colon & Rectum 4% Ovary 6% Uterus 3%
COME HOME Innovative Oncology Business Solutions, Inc.
Innovative Oncology Business Solutions, Inc. Breast Cancer Diagnostic/Therapeutic Pathway V11, April 2015 Required Structured Data Fields: ICD9 Code Stage Staging Components Performance Status Treatment
PERSONALISED COMBINATORIAL APPROACHES TO CLOSING DOWN ALL THE KEY ONCOGENIC DRIVERS THE AVERA TEAM
PERSONALISED COMBINATORIAL APPROACHES TO CLOSING DOWN ALL THE KEY ONCOGENIC DRIVERS THE AVERA TEAM OUR TEAM IS ADMINISTERING SEQUENCE-BASED DOUBLE AND TRIPLE THERAPIES NOW Coexpression of patterns of MYC
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
Emerging Advances in Metastatic Breast Cancer
Emerging Advances in Metastatic Breast Cancer Bryan P. Schneider, MD Assistant Professor of Medicine & Medical Molecular Genetics IU Simon Cancer Center AT LEAST THREE types of breast cancer TNBC HER2+
Alternativas terapéuticas en fenotipo triple negativo Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid
Alternativas terapéuticas en fenotipo triple negativo Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative Breast Cancer Immunohistochemistry
Customizing Therapeutic Strategies in the Management of Metastatic Breast Cancer
Customizing Therapeutic Strategies in the Management of Metastatic Breast Cancer Vandana G Abramson, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Breast Cancer
Identification of Potential Therapeutic Targets by Molecular and Genomic Profiling of 628 Cases of Uterine Serous Carcinoma
Identification of Potential Therapeutic Targets by Molecular and Genomic Profiling of 628 Cases of Uterine Serous Carcinoma Nathaniel L Jones 1, Joanne Xiu 2, Sandeep K. Reddy 2, Ana I. Tergas 1, William
Karel A. Dicke M.D., Ph.D.
Karel A. Dicke M.D., Ph.D. 1 Genomic Medicine Chemotherapy selected on the basis of biomarkers, i.e. proteins in the tumor. Chemotherapy is cytotoxic and kills tumor cells. Targeted Therapy (i.e. Precision
Contemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
Collaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation
Collaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation Dr Jenni Fairley Deputy Scheme Director (Molecular Pathology), GenQA, Edinburgh, UK From 1 st
Regimens highlighted in red contain an expensive drug that is not currently publicly funded for the regimen and treatment intent.
Palliative Breast Cancer Regimens The following table lists the evidence-informed regimens (both IV and non-iv) for breast cancer used in the palliative setting. It is expected that the prescribing oncologist
Dennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
Breast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?
Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen
Objectives: Describe poly-adp-ribose polymerase (PARP) inhibitors mechanism of action.
1 2 3 Role of PARP Inhibitors in Metastatic Breast Cancer Catie Chatowsky, PharmD PGY1 Pharmacy Resident Disclosure: I have nothing to disclose. Objectives: Describe poly-adp-ribose polymerase (PARP) inhibitors
Systemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
Nature Medicine: doi: /nm.3559
Supplementary Note 1. A sample alteration report. Each alteration nominated by PHIAL is curated to answer specific fields that are intended to guide physician interpretation. Gene Alteration Patient ID
CLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Corporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
ASCO 2017 BREAST CANCER HIGHLIGHTS
Post-ASCO 24 th June 2017, Dolce La Hulpe, Belgium ASCO 2017 BREAST CANCER HIGHLIGHTS Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
Manejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
New Drug development and Personalized Therapy in The Era of Molecular Medicine
New Drug development and Personalized Therapy in The Era of Molecular Medicine Ramesh K. Ramanathan MD Virginia G. Piper Cancer Center Translational Genomics Research Institute Scottsdale, AZ Clinical
Disclosures. Objectives. Novel Agents in the Systemic Management of Breast Cancer (Breast Cancer Update 2012) Peter Kabos, MD
Mountain States Cancer Conference 2012 Novel Agents in the Systemic Management of Breast Cancer (Breast Cancer Update 2012) Peter Kabos, MD University of Colorado Denver Disclosures No relevant disclosures
This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:
This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/81012/ This is the author s version of a work that was submitted to / accepted
Management of Inflammatory Breast Cancer: Collaboration is the path forward
Management of Inflammatory Breast Cancer: Collaboration is the path forward Massimo Cristofanilli, M.D., F.A.C.P. Professor of Medicine Associate Director of Translational Research and Precision Medicine
Breast Cancer. Breast Cancer. Established breast cancer risk factors. Established breast cancer risk factors. Cancer incidence.
Breast Cancer A buffet of breast cancer topics Wendy Y. Chen, MD MPH Dana-Farber Cancer Institute Brigham and Women s Hospital Disclosures: none Not related to anything presented in this lecture Wendy
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
Genomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France
Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients
4/13/2010. Silverman, Buchanan Breast, 2003
Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations
Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis
5/17/13 Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis Johannes Kratz, MD Post-doctoral Fellow, Thoracic Oncology Laboratory
Chemoresistance and targeted therapies in ovarian and endometrial cancers
/, 2017, Vol. 8, (No. 3), pp: 4008-4042 Chemoresistance and targeted therapies in ovarian and endometrial cancers Kevin Brasseur 1, Nicolas Gévry 2 and Eric Asselin 1 1 Research Group in Cellular Signaling,
ARTICLE IN PRESS. Critical Reviews in Oncology/Hematology xxx (2011) xxx xxx
Critical Reviews in Oncology/Hematology xxx (2011) xxx xxx Treatment of metastatic breast cancer: State-of-the-art, subtypes and perspectives Nagi S. El Saghir a,, Arafat Tfayli a, Hassan A. Hatoum a,
The Center for PERSONALIZED DIAGNOSTICS
The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine A joint initiative between The Department of Pathology and Laboratory Medicine & The Abramson Cancer Center The (CPD)
Breast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
José Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900 Research unit Versailles Saint-Quentin-en-Yvelines
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Verzenio) Reference Number: CP.PHAR.355 Effective Date: 10.24.17 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
Genomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
Targeted Agents In Breast Cancer. Wonderful Music With New Instruments
Targeted Agents In Breast Cancer Wonderful Music With New Instruments 1 Trends In Cancer Mortality In Women in US At This Rate We Will Beat Breast Cancer In 2040 Is the cause screening?? Is the cause better
Finding the Positives in Triple-Negative Breast Cancer:
Finding the Positives in Triple-Negative Breast Cancer: A Three-Part Live CME Webcast Series Seminar I Wednesday, March 3, 2010 Faculty Clifford Hudis, MD Lisa A Carey, MD Seminar II Thursday, March 11,
Subtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015
Subtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015 Ruth M. O Regan, MD Visiting Professor and Division Chief
Understanding and Optimizing Treatment of Triple Negative Breast Cancer
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology Program Leader, Gastrointestinal Oncology Department
Triple negative breast cancer 2014 GASCO Annual meeting September 5 th 2014, Atlanta, GA
Triple negative breast cancer 2014 GASCO Annual meeting September 5 th 2014, Atlanta, GA Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
The absolute benefit from chemotherapy for both older and younger patients appeared most significant in ER-negative populations.
Hello, my name is Diane Hecht, and I am a Clinical Pharmacy Specialist at the University of Texas MD Anderson Cancer Center. It s my pleasure to talk to you today about the role of chemotherapy in this
Breast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
Therapeutic Targets for Triple- Negative Breast Cancer: Focus on Platinums and EGFR Inhibition
Therapeutic Targets for Triple- Negative Breast Cancer: Focus on Platinums and EGFR Inhibition Lisa A Carey, MD Disclosures for Lisa A Carey, MD No real or apparent conflicts of interest to disclose Basal-Like
Update on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
GPS Cancer. The Era of Complete Genomics and Proteomics is Here. Advanced molecular profiling to inform personalized treatment strategies
MOLECULAR PROFILING GPS Cancer The Era of Complete Genomics and Proteomics is Here Advanced molecular profiling to inform personalized treatment strategies www.nanthealth.com What information do you need
Standard therapy of HER2-positive and triple negative metastatic breast cancer present and future
Standard therapy of HER2-positive and triple negative metastatic breast cancer present and future Jasna Trifunović, Jasna Pešić TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER The treatment of HER2-positive
UK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
2/21/2016. Cancer Precision Medicine: A Primer. Ovarian Cancer Statistics and Standard of Care in 2015 OUTLINE. Background
Cancer Precision Medicine: A Primer Rebecca C. Arend, MD Division of Gyn Oncology OUTLINE Background Where we are Where we have been Where we are going Targeted Therapy in Ovarian Cancer How to Individualized